These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7831243)

  • 21. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J
    J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic focus. The fluoroquinolones.
    James DG
    Br J Clin Pract; 1989 Feb; 43(2):66-7. PubMed ID: 2679837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 24. Rationale for the use of oral fluoroquinolones as empiric treatment of nursing home infections.
    McCue JD
    Arch Fam Med; 1994 Feb; 3(2):157-64. PubMed ID: 7994438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging resistance problems among respiratory tract pathogens.
    Lister PD
    Am J Manag Care; 2000 May; 6(8 Suppl):S409-18. PubMed ID: 10977480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.
    Blondeau JM
    Expert Opin Investig Drugs; 2001 Feb; 10(2):213-37. PubMed ID: 11178338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Trovafloxacin].
    Azanza JR; Ollero D; Sádaba B; García Quetglas E
    Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346
    [No Abstract]   [Full Text] [Related]  

  • 31. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolones.
    Hendershot EF
    Infect Dis Clin North Am; 1995 Sep; 9(3):715-30. PubMed ID: 7490440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Other communal respiratory pathogens and new fluoroquinolones].
    Cantón R; Loza E; Valdezate S; Baquero F
    Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():12-21; discussion 47-52. PubMed ID: 10344094
    [No Abstract]   [Full Text] [Related]  

  • 35. [Moxifloxacin: results of clinical use].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
    Wise R; Honeybourne D
    Eur Respir J; 1999 Jul; 14(1):221-9. PubMed ID: 10489856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of fluoroquinolones in children.
    Leibovitz E
    Curr Opin Pediatr; 2006 Feb; 18(1):64-70. PubMed ID: 16470165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.